Related Experiment Video
Updated: May 22, 2026
07:20
Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
Transdermal hyoscine induced unilateral mydriasis
Breffni Hannon1, Valerie Jennings, Marie Twomey
1Palliative Medicine Department, Our Lady's Children's Hospital, Dublin, Ireland. breffnilhannon@yahoo.co.uk
BMJ Case Reports
|May 19, 2012
Summary
Transdermal scopolamine, used for chemotherapy nausea, can cause unilateral mydriasis (dilated pupil) in teenagers. This case highlights potential ocular side effects of this antiemetic drug delivery system.
Area of Science:
- Pharmacology
- Ophthalmology
- Oncology
Background:
- Transdermal hyoscine hydrobromide (scopolamine) is utilized for managing chemotherapy-induced nausea and vomiting (CINV).
- The transdermal delivery system offers sustained drug release, but potential side effects require consideration.
Observation:
- A case study involving a teenager experiencing unilateral mydriasis (pupil dilation) is presented.
- This ocular side effect occurred after the administration of transdermal scopolamine for CINV.
Findings:
- The study discusses the specific ocular side effects linked to transdermal scopolamine.
- Unilateral mydriasis is identified as a potential adverse event associated with this antiemetic agent and delivery method.
Implications:
- This finding underscores the importance of monitoring for ocular side effects in patients using transdermal scopolamine.
- It suggests a need for further research into the safety profile and optimal use of transdermal hyoscine in adolescent oncology patients.
Related Concept Videos
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:28Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...